SRC and systemic sclerosis: Despite the identification of possible risk factors, as the use of glucocorticoids and the presence of autoantibodies directed against RNA polymerase III, SRC develops in about 10% percent of SSc patients, most commonly within 3 to 5 years of diagnosis, and in those with dcSSC.